Pulmatrix

Inhaled Respiratory Disease Therapies

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator...

Founded in 2003
Homepage: http://www.pulmatrix.com/
Total money raised: $53.4M

02421 99 Hayden Avenue
Suite 390
Lexington
USA MA

Phone: 781-357-2333

Updated on Sep 4, 2012
Pulmatrix at CrunchBase

Robert Clarke CEO
Eva Jack CBO
Kevin Bitterman Board Observer
Past

August, 2011

Pulmatrix raised $14M in a Series B round from Polaris Partners, 5AM Ventures, ARCH Venture Partners, and Novartis Venture Fund

Pulmatrix Secures a $14 million Financing to Advance Clinical Programs in COPD and Cystic Fibrosis

eon.businesswire.com

December, 2010

Pulmatrix raised $5.7M in grant round

Pulmatrix Secures $5.7M Darpa Grant, Hires Eva Jack As CBO

fis.dowjones.com

November, 2009

Pulmatrix raised $30.2M in a Series B round from ARCH Venture Partners, Novartis Bioventures, Polaris Partners, and 5AM Ventures

Xconomy Boston

March, 2009

Pulmatrix raised $3.5M in a Series A round from Polaris Partners and 5AM Ventures

Mass High Tech

masshightech.com

2003

Pulmatrix was founded in 2003